VCYT on XNAS, Health Care, Veracyte, Inc., job postings
Measures activity, not value. Not investment advice.
Shares fell 46% in one month despite revenue up 17% to $581.8M over 12 months.
BadShort interest at 12% of shares, 8.2 days to cover
Written by AI from the data on this page, 22 Nov 2026. Not investment advice.
Profile and fundamentals
From its SEC filings, 12 months to 30 Sep 2026
Veracyte Inc is a genomic diagnostics company. The group empowers clinicians with the insights necessary to guide and assure patients at pivotal moments in the race to diagnose and treat cancer. It offers tests for prostate cancer (Decipher Prostate), thyroid cancer (Afirma), breast cancer (Prosigna), and bladder cancer (Decipher Bladder).
expected around 11 Jan 2027 (an estimate: a year ago it reported on 12 Jan 2026)
Revenue and net income per quarter. Quarter to 30 Sep 2026: revenue $151.8M, net income $31.5M.
31 Dec 2021RevenueNet incomeNet losstallest bar $151.8M30 Sep 2026
See the numbers
Quarter to
Revenue
Net income
30 Sep 2026
$151.8M
$31.5M
30 Jun 2026
$150.3M
$25.5M
31 Mar 2026
$139.1M
$28.7M
31 Dec 2025
$140.6M
$41.1M
30 Sep 2025
$131.9M
$19.1M
30 Jun 2025
$130.2M
-$980K
31 Mar 2025
$114.5M
$7.0M
31 Dec 2024
$118.6M
$5.1M
30 Sep 2024
$115.9M
$15.2M
30 Jun 2024
$114.4M
$5.7M
31 Mar 2024
$96.8M
-$1.9M
31 Dec 2023
$98.2M
-$28.3M
30 Sep 2023
$90.1M
-$29.6M
30 Jun 2023
$90.3M
-$8.4M
31 Mar 2023
$82.4M
-$8.1M
31 Dec 2022
$80.3M
-$3.8M
30 Sep 2022
$75.6M
-$8.7M
30 Jun 2022
$72.9M
-$9.5M
31 Mar 2022
$67.8M
-$14.5M
31 Dec 2021
$67.3M
-$10.5M
Fundamentals, 12 months to 30 Sep 2026
Measure
Latest
Year before
Peer median
RevenueiSales over the last 12 months reported.
$581.8M
$495.1M
Revenue growthiRevenue of the last 12 months compared with the 12 months before.
+17%
+17%
Net incomeiProfit after all costs and taxes over the last 12 months reported. Negative is a loss.
$126.8M
$30.3M
EPS (diluted)iEarnings per share: net income divided by the shares, counting options and convertibles. Left blank when the figures as filed do not fit today's share count (after a split).
$1.54
$0.38
Gross marginiWhat is left of each dollar of sales after the direct cost of making the product or service.
72.0%
68.5%
33.5%
Operating marginiOperating income as a share of sales: profit from the business before interest and taxes.
17.1%
5.0%
-8.2%
Net marginiNet income as a share of sales: what the owners keep of each dollar sold.
21.8%
6.1%
-5.9%
Return on equityiNet income of the last 12 months divided by shareholders' equity (the average of the latest balance sheet and the one a year earlier): the profit made on the owners' money.
9.4%
-10.1%
Free cash flowiCash from operations minus capital spending over the last 12 months: cash the business produced.
$161.9M
$98.2M
CashiCash, cash equivalents and short-term investments on the latest balance sheet.
$199.8M
$315.6M
DebtiShort- and long-term borrowings on the latest balance sheet. Operating leases are not counted.
$0
$0
Net debtiDebt minus cash. Negative means the company holds more cash than it owes (net cash).
-$199.8M (net cash)
-$315.6M
Debt to equityiDebt divided by shareholders' equity on the latest balance sheet: how much is borrowed for each dollar the owners have in the company. Blank when equity is negative.
0.0
0.16
Book value per shareiShareholders' equity (assets minus liabilities) on the latest balance sheet divided by the shares outstanding.
$17.76
P/EiPrice to earnings: market cap divided by net income of the last 12 months. What investors pay for one dollar of yearly profit. Blank when the company made a loss.
16.0
29.1
P/SiPrice to sales: market cap divided by revenue of the last 12 months.
3.5
3.6
EV/SalesiEnterprise value (market cap plus debt minus cash) divided by revenue of the last 12 months.
3.1
2.6
P/BiPrice to book: market cap divided by shareholders' equity on the latest balance sheet. Blank when equity is negative.
1.4
2.8
Latest = 12 months to 30 Sep 2026; balance-sheet lines at its end. Peer median: companies in the same industry (SIC code), or the sector when the industry is small.
Peers nearest by market cap, its own industry first
Insider Buy/Sell iShares the company's insiders (directors, officers and owners of 10% or more) bought minus what they sold on the open market in the last 90 days, from their Form 4 filings.
-$2.9M
bought $0, sold $2.9M
Institutional holders iThe number of institutional investment managers (13F filers: funds, pensions, asset managers) reporting the stock, compared with the quarter before. 13F reports are public 45 days after quarter end and show long positions only.
+4.9%
382 13F filers vs 364
Institutional ownership iShares held by 13F filers at the latest quarter end, divided by the shares outstanding in the company's latest filing. Above 100% usually means a stale share count or double counting, and is marked.
over 100%
94.7M shares held by 13F filers (30 Sep 2026) of 80.7M outstanding (30 Oct 2026); above 100%: the share count is probably stale
Short interest iShares sold short and not yet bought back, divided by the shares outstanding in the company's latest filing. From FINRA's latest short interest report: FINRA reports twice a month and publishes 7 business days after the settlement date. Above 100% means a stale share count, and is marked.
12%
9.6M shares sold short (30 Oct 2026) of 80.7M outstanding (30 Oct 2026)
Days to cover iShort interest divided by the stock's average daily trading volume, as FINRA publishes it: how many days of normal trading it would take short sellers to buy back every share. Latest report.
8.2
9.6M shares sold short (30 Oct 2026) divided by the stock's average daily volume, as FINRA publishes it
Short interest change iHow the number of shares sold short changed between FINRA's two latest reports, about two weeks apart.
-2.7%
9.8M shares sold short in the report before, 9.6M on 30 Oct 2026
Short sale volume iShare of the stock's latest daily volume on FINRA-reported off-exchange venues that was sold short. Market makers sell short routinely, so 40% to 50% is normal; compare it with the company's own 1-year average in the cell's details. A daily flow, not short interest.
45%
45% of off-exchange volume on 20 Nov 2026 was short sales; 1-year average 62%
Open jobs iJob postings open on the company's own careers site today, where we track it. Blank when we do not track this company's careers site yet.
24
Tracked since 20 Nov 2026
Open jobs change iHow the number of open job postings changed over the last 30 days: total hiring demand, any job, any country. Shown only once we have tracked the company for 30 days.
–
Tracking started 20 Nov 2026; the change shows after 30 days.
Employees iTotal staff the company reported in its latest annual report (10-K), with the change from the year before when both years are reported.
–
No headcount in its annual reports in our data.
Visa hiring (foreign workers) iApplications to hire foreign specialists on H-1B and E-3 visas certified by the Labor Department in the last 12 months, compared with the 12 months before. This is NOT total hiring: most hires need no visa. Open jobs shows total hiring where we track it.
–
No data for this company
Revenue growth iSales in the latest reported quarter compared with the same quarter a year earlier.
+15%
$151.8M vs $131.9M (quarter ended 30 Sep 2026)
Capital spending iMoney spent on buildings, machines and equipment in the latest quarter, compared with the same quarter a year earlier.
-16%
$2.3M vs $2.8M (quarter ended 30 Sep 2026)
Federal contracts iMoney the US government committed to the company in contracts and grants over the last 12 months.
$3.5M
the 12 months before: $1.2M
Lobbying iWhat the company reported spending on federal lobbying over the last four quarters.
–
No data for this company
Layoff notices iWorkers named in state WARN layoff notices over the last 12 months (employers must file them 60 days before a large layoff).
–
No data for this company
News (7d) iArticles about the company published in the last 7 days, from our Google News collection (one search per company, every half hour). Blank when we do not collect news for this company.
5
5 articles in the last 7 days; its usual week has 3 (the median of the 26 weeks before).
News vs usual iArticles in the last 7 days divided by the company's usual week: the median week of the 26 weeks before. Blank when the usual week has fewer than one article.
1.7×
5 articles in the last 7 days; its usual week has 3.
Price $25.13 on 20 Nov 2026, -38% over 12 months (12-month range $24.00 to $60.49)
Sharp change
8-K and other filings
Lobbying filing
Insider net buying (open market). Insiders sold a net $18.6M in the last 12 months (the 12 months before: -$10.3M).H-1B/E-3 applications certified. H-1B/E-3 applications certified: 12 published in the last 12 months, +50% on the 12 months before.Revenue per quarter. Revenue $151.8M in the latest quarter, +15% on a year earlier.Capital spending per quarter. Capital spending $2.3M in the latest quarter, -16% on a year earlier.Institutional holders (13F filers). 382 13F filers reported holding it in the latest 13F quarter, +36% on a year earlier.Federal obligations. Federal obligations: $3.4M published in the last 12 months, +56% on the 12 months before.Lobbying spend. Lobbying spend: $0 published in the last 12 months.
Every point sits on the day the fact became public (filing acceptance or publication), not the day it happened; prices through 20 Nov 2026. Hover or tap a marker for the fact; click it for the evidence or the source. No data here for: workers in warn layoff notices.
Quarter ended 31 Dec 2021: $67.3M, +95% on a year earlier; public on 1 Mar 2022
Quarter ended 31 Mar 2022: $67.8M, +85% on a year earlier; public on 5 May 2022
Quarter ended 30 Jun 2022: $72.9M, +32% on a year earlier; public on 4 Aug 2022
Quarter ended 30 Sep 2022: $75.6M, +25% on a year earlier; public on 4 Nov 2022
Quarter ended 31 Dec 2022: $80.3M, +19% on a year earlier; public on 2 Mar 2023
Quarter ended 31 Mar 2023: $82.4M, +22% on a year earlier; public on 6 May 2023
Quarter ended 30 Jun 2023: $90.3M, +24% on a year earlier; public on 10 Aug 2023
Quarter ended 30 Sep 2023: $90.1M, +19% on a year earlier; public on 9 Nov 2023
Quarter ended 31 Dec 2023: $98.2M, +22% on a year earlier; public on 1 Mar 2024
Quarter ended 31 Mar 2024: $96.8M, +17% on a year earlier; public on 9 May 2024
Quarter ended 30 Jun 2024: $114.4M, +27% on a year earlier; public on 8 Aug 2024
Quarter ended 30 Sep 2024: $115.9M, +29% on a year earlier; public on 8 Nov 2024
Quarter ended 31 Dec 2024: $118.6M, +21% on a year earlier; public on 1 Mar 2025
Quarter ended 31 Mar 2025: $114.5M, +18% on a year earlier; public on 9 May 2025
Quarter ended 30 Jun 2025: $130.2M, +14% on a year earlier; public on 8 Aug 2025
Quarter ended 30 Sep 2025: $131.9M, +14% on a year earlier; public on 6 Nov 2025
Quarter ended 31 Dec 2025: $140.6M, +19% on a year earlier; public on 27 Feb 2026
Quarter ended 31 Mar 2026: $139.1M, +21% on a year earlier; public on 7 May 2026
Quarter ended 30 Jun 2026: $150.3M, +15% on a year earlier; public on 1 Aug 2026
Quarter ended 30 Sep 2026: $151.8M, +15% on a year earlier; public on 6 Nov 2026
Capital spending per quarter
Quarter ended 31 Dec 2021: $841K, -5.3% on a year earlier; public on 1 Mar 2022
Quarter ended 31 Mar 2022: $2.5M, +105% on a year earlier; public on 5 May 2022
Quarter ended 30 Jun 2022: $2.5M, +64% on a year earlier; public on 4 Aug 2022
Quarter ended 30 Sep 2022: $1.7M, -5.4% on a year earlier; public on 4 Nov 2022
Quarter ended 31 Dec 2022: $1.9M, +123% on a year earlier; public on 2 Mar 2023
Quarter ended 31 Mar 2023: $993K, -60% on a year earlier; public on 6 May 2023
Quarter ended 30 Jun 2023: $3.7M, +46% on a year earlier; public on 10 Aug 2023
Quarter ended 30 Sep 2023: $2.8M, +63% on a year earlier; public on 9 Nov 2023
Quarter ended 31 Dec 2023: $2.5M, +33% on a year earlier; public on 1 Mar 2024
Quarter ended 31 Mar 2024: $2.1M, +115% on a year earlier; public on 9 May 2024
Quarter ended 30 Jun 2024: $2.8M, -25% on a year earlier; public on 8 Aug 2024
Quarter ended 30 Sep 2024: $2.2M, -20% on a year earlier; public on 8 Nov 2024
Quarter ended 31 Dec 2024: $4.1M, +66% on a year earlier; public on 1 Mar 2025
Quarter ended 31 Mar 2025: $1.8M, -15% on a year earlier; public on 9 May 2025
Quarter ended 30 Jun 2025: $1.3M, -54% on a year earlier; public on 8 Aug 2025
Quarter ended 30 Sep 2025: $2.8M, +25% on a year earlier; public on 6 Nov 2025
Quarter ended 31 Dec 2025: $3.8M, -8.7% on a year earlier; public on 27 Feb 2026
Quarter ended 31 Mar 2026: $3.0M, +63% on a year earlier; public on 7 May 2026
Quarter ended 30 Jun 2026: $2.9M, +122% on a year earlier; public on 1 Aug 2026
Quarter ended 30 Sep 2026: $2.3M, -16% on a year earlier; public on 6 Nov 2026
Institutional holders (13F filers)
31 Dec 2021 report: 195; public on 14 Feb 2022
31 Mar 2022 report: 193; public on 16 May 2022
30 Jun 2022 report: 182; public on 15 Aug 2022
30 Sep 2022 report: 193; public on 14 Nov 2022
31 Dec 2022 report: 207; public on 14 Feb 2023
31 Mar 2023 report: 217; public on 15 May 2023
30 Jun 2023 report: 214; public on 14 Aug 2023
30 Sep 2023 report: 220; public on 14 Nov 2023
31 Dec 2023 report: 236; public on 14 Feb 2024
31 Mar 2024 report: 232; public on 15 May 2024
30 Jun 2024 report: 228; public on 14 Aug 2024
30 Sep 2024 report: 281; public on 14 Nov 2024
31 Dec 2024 report: 307; public on 14 Feb 2025
31 Mar 2025 report: 274; public on 15 May 2025
30 Jun 2025 report: 266; public on 14 Aug 2025
30 Sep 2025 report: 281; public on 14 Nov 2025
31 Dec 2025 report: 315; public on 17 Feb 2026
31 Mar 2026 report: 330; public on 15 May 2026
30 Jun 2026 report: 364; public on 14 Aug 2026
30 Sep 2026 report: 382; public on 16 Nov 2026
Federal obligations
Month from 1 Nov 2021: $12K published
Month from 1 Dec 2021: -$10K published
Month from 1 Jan 2022: $70K published
Month from 1 Feb 2022: -$113K published
Month from 1 Mar 2022: $180K published
Month from 1 Apr 2022: -$28K published
Month from 1 Jun 2022: $33K published
Month from 1 Jul 2022: $59K published
Month from 1 Aug 2022: $67K published
Month from 1 Sep 2022: $62K published
Month from 1 Oct 2022: $78K published
Month from 1 Nov 2022: $17K published
Month from 1 Jan 2023: $42K published
Month from 1 Feb 2023: $363K published
Month from 1 Apr 2023: $222K published
Month from 1 May 2023: $76K published
Month from 1 Jun 2023: $212K published
Month from 1 Jul 2023: -$18K published
Month from 1 Sep 2023: $11K published
Month from 1 Oct 2023: -$54K published
Month from 1 Nov 2023: $168K published
Month from 1 Dec 2023: $165K published
Month from 1 Jan 2024: $252K published
Month from 1 Feb 2024: $23K published
Month from 1 Mar 2024: $92K published
Month from 1 Apr 2024: $407K published
Month from 1 May 2024: -$110K published
Month from 1 Jun 2024: -$26K published
Month from 1 Jul 2024: $112K published
Month from 1 Aug 2024: -$33K published
Month from 1 Sep 2024: -$7K published
Month from 1 Oct 2024: $59K published
Month from 1 Nov 2024: $113K published
Month from 1 Dec 2024: $26K published
Month from 1 Jan 2025: $28K published
Month from 1 Feb 2025: $729K published
Month from 1 Mar 2025: $303K published
Month from 1 Apr 2025: $25K published
Month from 1 May 2025: -$10K published
Month from 1 Jun 2025: $69K published
Month from 1 Jul 2025: -$80K published
Month from 1 Aug 2025: -$31K published
Month from 1 Sep 2025: $163K published
Month from 1 Oct 2025: $514K published
Month from 1 Nov 2025: $434K published
Month from 1 Dec 2025: $203K published
Month from 1 Jan 2026: $1.0M published
Month from 1 Feb 2026: $216K published
Month from 1 Mar 2026: $517K published
Month from 1 Apr 2026: -$42K published
Month from 1 May 2026: $75K published
Month from 1 Jun 2026: $467K published
Month from 1 Jul 2026: -$71K published
Month from 1 Aug 2026: $134K published
Month from 1 Sep 2026: -$82K published
Month from 1 Oct 2026: $382K published
Month from 1 Nov 2026: $557K published
Lobbying spend
Quarter from 1 Jan 2022: $30K published
Quarter from 1 Apr 2022: $30K published
Quarter from 1 Jul 2022: $30K published
Quarter from 1 Oct 2022: $30K published
Quarter from 1 Jan 2023: $30K published
What is unusual now
Nothing unusual in the last 90 days: no change appeared. Its most unusual measure now is research and development expense, quarter at $32.2M (30 Sep 2026), 1.8× its normal quarter; higher than 100% of its own history.
24 open postings; careers site tracked since 20 Nov 2026. Most in Research & science 21%, Finance & accounting 12%, Legal, policy & compliance 12%, Sales & business development 12%.
Reported lobbying spend: $30K in Q4 2022, $30K in Q3 2022. Rows are lobbying firms hired or let go; amounts are reported per quarter, not per firm here.
Date
Change
Lobbying firm
Issue
Source
31 Dec 2022
Ended
Todd Strategy Groupfor Veracyte, Inc.
Diagnostics coverage and reimbursement. H.R.4128 - VALID Act of 2021.Health issues
Implementation of PL 113-93 (H.R. 4302): Protecting Access to Medicare Act of 2014. Implementation of changes to Medicare payments for clinical laboratory tests. Medicare Treatment of Outpatient Reimbursement for Laboratory tests. FDA regulation of laboratory developed tests.Medicare/Medicaid, MED
Two or more unrelated kinds of records unusual within 30 days
4 Aug 2020confirmed
Confirmed across sources Filings + Financials and Lobbying
Veracyte(VCYT): lobbying on a new issue, while it reported revenue of $20.7M for the quarter ended 30 Jun 2020, 31% below the same quarter last year. Two unrelated kinds of activity within 21 days.
Lobbying: Lobbying on a new issue, became public on 14 Jul 2020
Financials: Quarterly revenue change, became public on 4 Aug 2020
The quarter ended 30 Jun 2020 against the 8 quarters before it.
this quarterearliernormal: $29.6MSee the evidence (2 changes)
Lobbying: Lobbying on a new issue became public on 14 Jul 2020
Veracyte lobbying on a new issue.
New
['HCR']
Rule
only points whose every posting (and value revision) is at or before as_of
Field
issue_codes
Metric
lobbying.filings_count
Point id
12719736
Financials: Quarterly revenue change became public on 4 Aug 2020
Veracyte reported revenue of $20.7M for the quarter ended 30 Jun 2020, 31% below the same quarter last year.
This period
$20.7M (the quarter ended 30 Jun 2020)
Normal quarter (median of 8 earlier)
$29.6M
Typical spread (median absolute deviation)
$1.4M
How far from its usual level
-3.0
Same quarter last year
$30.1M
History used
3,013 days
the quarter ended 30 Jun 20208 earlier quartersnormal: $29.6M
Fires when the period is at least 3.0 robust standard deviations away from the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.
Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.
15 Jan 2019confirmed
Confirmed across sources Institutional holdings and Filings + Financials and Short interest and volume
Veracyte(VCYT): saw 37 13F filers open a new position in the quarter ended 30 Sep 2018, 3.7× the same quarter last year; it also had 2.2M shares sold short in the 31 Dec 2018 report, 3.2× the same report last year; and it reported revenue of $25.8M for the quarter ended 31 Dec 2018, 1.3× the same quarter last year. Three unrelated kinds of activity within 56 days.
Institutional holdings: Many funds opening a new position, became public on 14 Nov 2018
Short interest and volume: Short interest spike, became public on 11 Jan 2019
Short interest and volume: Short interest spike, became public on 26 Jan 2019
Financials: Quarterly revenue change, became public on 26 Feb 2019
The quarter ended 30 Sep 2018 against the 8 quarters before it.
this quarterearliernormal: 11See the evidence (4 changes)
Institutional holdings: Many funds opening a new position became public on 14 Nov 2018
Veracyte saw 37 13F filers open a new position in the quarter ended 30 Sep 2018, 3.7× the same quarter last year.
This period
37 (the quarter ended 30 Sep 2018)
Normal quarter (median of 8 earlier)
11
Typical spread (median absolute deviation)
3.5
How far from its usual level
+5.0
Same quarter last year
10
History used
1,734 days
the quarter ended 30 Sep 20188 earlier quartersnormal: 11
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.
Short interest and volume: Short interest spike became public on 11 Jan 2019
Veracyte had 2.2M shares sold short in the 31 Dec 2018 report, 3.2× the same report last year.
This period
2.2M (the 31 Dec 2018 report)
Normal report (median of 20 earlier)
817K
Typical spread (median absolute deviation)
137K
How far from its usual level
+6.5
Same report last year
668K
History used
367 days
the 31 Dec 2018 report20 earlier reportsnormal: 817K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 26 Jan 2019
Veracyte had 1.8M shares sold short in the 15 Jan 2019 report, 2.5× the same report last year.
This period
1.8M (the 15 Jan 2019 report)
Normal report (median of 21 earlier)
823K
Typical spread (median absolute deviation)
154K
How far from its usual level
+4.5
Same report last year
742K
History used
382 days
the 15 Jan 2019 report21 earlier reportsnormal: 823K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Financials: Quarterly revenue change became public on 26 Feb 2019
Veracyte reported revenue of $25.8M for the quarter ended 31 Dec 2018, 1.3× the same quarter last year.
This period
$25.8M (the quarter ended 31 Dec 2018)
Normal quarter (median of 8 earlier)
$19.0M
Typical spread (median absolute deviation)
$1.3M
How far from its usual level
+3.6
Same quarter last year
$19.6M
History used
2,466 days
the quarter ended 31 Dec 20188 earlier quartersnormal: $19.0M
Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.
Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.
Timeline
Changes and notable records, by the date each became public
saw 62 13F filers open a new position in the quarter ended 30 Sep 2025, 7.5% below the same quarter last year.
Same quarter last year: 67; its normal quarter is 28.5.
See the evidence
This period
62 (the quarter ended 30 Sep 2025)
Normal quarter (median of 8 earlier)
28.5
Typical spread (median absolute deviation)
5
How far from its usual level
+4.5
Same quarter last year
67
History used
4,291 days
the quarter ended 30 Sep 20258 earlier quartersnormal: 28.5
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.
had 9.1M shares sold short in the 15 Sep 2025 report, 2.6× the same report last year.
Same report last year: 3.5M; its normal report is 3.4M.
See the evidence
This period
9.1M (the 15 Sep 2025 report)
Normal report (median of 24 earlier)
3.4M
Typical spread (median absolute deviation)
687K
How far from its usual level
+5.6
Same report last year
3.5M
History used
2,817 days
the 15 Sep 2025 report24 earlier reportsnormal: 3.4M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 8.0M shares sold short in the 29 Aug 2025 report, 2.7× the same report last year.
Same report last year: 2.9M; its normal report is 3.3M.
See the evidence
This period
8.0M (the 29 Aug 2025 report)
Normal report (median of 24 earlier)
3.3M
Typical spread (median absolute deviation)
511K
How far from its usual level
+6.2
Same report last year
2.9M
History used
2,800 days
the 29 Aug 2025 report24 earlier reportsnormal: 3.3M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 8.2M shares sold short in the 15 Aug 2025 report, 2.6× the same report last year.
Same report last year: 3.1M; its normal report is 3.3M.
See the evidence
This period
8.2M (the 15 Aug 2025 report)
Normal report (median of 24 earlier)
3.3M
Typical spread (median absolute deviation)
380K
How far from its usual level
+8.6
Same report last year
3.1M
History used
2,786 days
the 15 Aug 2025 report24 earlier reportsnormal: 3.3M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 9.1M shares sold short in the 31 Jul 2025 report, 3.1× the same report last year.
Same report last year: 3.0M; its normal report is 3.2M.
See the evidence
This period
9.1M (the 31 Jul 2025 report)
Normal report (median of 24 earlier)
3.2M
Typical spread (median absolute deviation)
284K
How far from its usual level
+13.9
Same report last year
3.0M
History used
2,771 days
the 31 Jul 2025 report24 earlier reportsnormal: 3.2M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 6.1M shares sold short in the 15 Jul 2025 report, 2.0× the same report last year.
Same report last year: 3.1M; its normal report is 3.1M.
See the evidence
This period
6.1M (the 15 Jul 2025 report)
Normal report (median of 24 earlier)
3.1M
Typical spread (median absolute deviation)
230K
How far from its usual level
+8.7
Same report last year
3.1M
History used
2,755 days
the 15 Jul 2025 report24 earlier reportsnormal: 3.1M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 5.9M shares sold short in the 13 Jun 2025 report, 1.3× the same report last year.
Same report last year: 4.5M; its normal report is 3.1M.
See the evidence
This period
5.9M (the 13 Jun 2025 report)
Normal report (median of 24 earlier)
3.1M
Typical spread (median absolute deviation)
206K
How far from its usual level
+9.0
Same report last year
4.5M
History used
2,723 days
the 13 Jun 2025 report24 earlier reportsnormal: 3.1M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 5.5M shares sold short in the 30 May 2025 report, 1.2× the same report last year.
Same report last year: 4.4M; its normal report is 3.1M.
See the evidence
This period
5.5M (the 30 May 2025 report)
Normal report (median of 24 earlier)
3.1M
Typical spread (median absolute deviation)
206K
How far from its usual level
+7.5
Same report last year
4.4M
History used
2,709 days
the 30 May 2025 report24 earlier reportsnormal: 3.1M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 5.2M shares sold short in the 15 May 2025 report, 1.2× the same report last year.
Same report last year: 4.5M; its normal report is 3.1M.
See the evidence
This period
5.2M (the 15 May 2025 report)
Normal report (median of 24 earlier)
3.1M
Typical spread (median absolute deviation)
206K
How far from its usual level
+6.7
Same report last year
4.5M
History used
2,694 days
the 15 May 2025 report24 earlier reportsnormal: 3.1M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 5.6M shares sold short in the 30 Apr 2025 report, 1.3× the same report last year.
Same report last year: 4.4M; its normal report is 3.1M.
See the evidence
This period
5.6M (the 30 Apr 2025 report)
Normal report (median of 24 earlier)
3.1M
Typical spread (median absolute deviation)
206K
How far from its usual level
+7.8
Same report last year
4.4M
History used
2,679 days
the 30 Apr 2025 report24 earlier reportsnormal: 3.1M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 5.1M shares sold short in the 15 Apr 2025 report, 1.4× the same report last year.
Same report last year: 3.6M; its normal report is 3.1M.
See the evidence
This period
5.1M (the 15 Apr 2025 report)
Normal report (median of 24 earlier)
3.1M
Typical spread (median absolute deviation)
206K
How far from its usual level
+6.4
Same report last year
3.6M
History used
2,664 days
the 15 Apr 2025 report24 earlier reportsnormal: 3.1M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
saw 67 13F filers open a new position in the quarter ended 30 Sep 2024, 2.9× the same quarter last year.
Same quarter last year: 23; its normal quarter is 28.5.
See the evidence
This period
67 (the quarter ended 30 Sep 2024)
Normal quarter (median of 8 earlier)
28.5
Typical spread (median absolute deviation)
5
How far from its usual level
+5.2
Same quarter last year
23
History used
3,926 days
the quarter ended 30 Sep 20248 earlier quartersnormal: 28.5
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.
reported revenue of $67.3M for the quarter ended 31 Dec 2021, 1.9× the same quarter last year.
Same quarter last year: $34.5M; its normal quarter is $32.8M.
See the evidence
This period
$67.3M (the quarter ended 31 Dec 2021)
Normal quarter (median of 8 earlier)
$32.8M
Typical spread (median absolute deviation)
$3.5M
How far from its usual level
+6.7
Same quarter last year
$34.5M
History used
3,562 days
the quarter ended 31 Dec 20218 earlier quartersnormal: $32.8M
Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.
reported revenue of $60.4M for the quarter ended 30 Sep 2021, 1.9× the same quarter last year.
Same quarter last year: $31.1M; its normal quarter is $31.1M.
See the evidence
This period
$60.4M (the quarter ended 30 Sep 2021)
Normal quarter (median of 8 earlier)
$31.1M
Typical spread (median absolute deviation)
$2.4M
How far from its usual level
+8.2
Same quarter last year
$31.1M
History used
3,470 days
the quarter ended 30 Sep 20218 earlier quartersnormal: $31.1M
Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.
reported revenue of $55.1M for the quarter ended 30 Jun 2021, 2.7× the same quarter last year.
Same quarter last year: $20.7M; its normal quarter is $31.0M.
See the evidence
This period
$55.1M (the quarter ended 30 Jun 2021)
Normal quarter (median of 8 earlier)
$31.0M
Typical spread (median absolute deviation)
$1.1M
How far from its usual level
+7.7
Same quarter last year
$20.7M
History used
3,378 days
the quarter ended 30 Jun 20218 earlier quartersnormal: $31.0M
Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.
Showing the newest 40 of 84 entries; narrow the window or the kind of data to see older ones.
Not listed: 331 routine records (quarterly and annual reports, results releases, other 8-K items, material agreements and individual insider sales), counted over all history.
Identifiers and sources
How records are matched to this company, and what each source holds for it
Cik
0001384101
Ticker
VCYT
Domain
veracyte.com
Employer name
Veracyte, Inc. (1 unverified)
Hq location
CA|SOUTH SAN FRANCISCO|94080 (1 unverified)
Lobbying client
veracyte
Name
C2i Genomics Ltd, CALDEROME INC, Legal Entity Name, Veracyte Diagnostics, LLC and 6 more
Uei
DKKCNLTYT2A1, JS7GBP6LCMN6
DOL H-1B labor condition applications and PERM certifications245 data points2 Dec 2019 to 28 Sep 2026
Federal lobbying disclosures (LDA)2 records, 84 data points1 Jan 2016 to 31 Dec 2022
SEC Form 13F institutional holdings468 data points31 Dec 2013 to 30 Sep 2026
SEC EDGAR filings (8-K items, S-1, Form D, 10-K/10-Q)162 records4 Mar 2016 to 5 Nov 2026
SEC XBRL company facts (revenue, capex, R&D, backlog...)984 data points31 Dec 2010 to 30 Oct 2026
SEC Form 4 insider transactions213 records, 652 data points1 Jun 2016 to 28 Oct 2026
FINRA short interest (twice monthly)624 data points29 Dec 2017 to 30 Oct 2026
FINRA daily short sale volume (off-exchange)4178 data points1 Aug 2018 to 20 Nov 2026
USASpending.gov federal awards864 data points23 Oct 2012 to 20 Nov 2026